Presentation is loading. Please wait.

Presentation is loading. Please wait.

Fig S1 Relative mRNA expression MCF7 pS2 * * * * * CCNG2 * * * * * * RPRM * * * * KLF6 * * * * * * CLDN4 * * * CERK * * * EFEMP1 * * * ENC1 * * BIK * *

Published byGeorgiana Lewis Modified over 9 years ago

Similar presentations

Presentation on theme: "Fig S1 Relative mRNA expression MCF7 pS2 * * * * * CCNG2 * * * * * * RPRM * * * * KLF6 * * * * * * CLDN4 * * * CERK * * * EFEMP1 * * * ENC1 * * BIK * *"— Presentation transcript:

1 Fig S1 Relative mRNA expression MCF7 pS2 * * * * * CCNG2 * * * * * * RPRM * * * * KLF6 * * * * * * CLDN4 * * * CERK * * * EFEMP1 * * * ENC1 * * BIK * * * * * * HBP1 * * * * * CXCR4 * * * * RAP1GA1 * * * * CDH3 * * BMP7 * * MXD4 * * * * MUC1 * * * * NDRG1 * * * RBL2 * BAKp21PLK2 * DUSP4 * * * 4 hr8 hr24 hr4 hr8 hr24 hr4 hr8 hr24 hr4 hr8 hr24 hr Fig S1: Identification of estrogen-repressed genes in MCF7 cells. q-RT-PCR was used to confirm the estrogen-mediated repression of candidate genes identified from microarray data. The relative mRNA expression is depicted as ligand-mediated fold change compared to vehicle control. MCF7 cells were treated for 4, 8, or 24 hours with either vehicle, estrogen (E2), or a combination of E2 and ICI (E2+ICI). The data are an average of three replicates + SEM. A t-test analysis was performed in which the E2 treatment group was compared to the vehicle group and the E2+ICI group was compared to the E2 group (* p < 0.05).

2 Fig S2 Fig S2: Estrogen-mediated repression of selected genes in breast cancer cells. q-RT-PCR was used to confirm the estrogen-mediated repression of candidate genes identified from microarray data. The relative mRNA expression is depicted as ligand-mediated fold change compared to vehicle control. (A) ZR-75-1 and (B) T47D cells were treated for 4, 8, or 24 hours with either vehicle, estrogen (E2), or a combination of E2 and ICI. The data are an average of three replicates + SEM. A t-test analysis was performed in which the E2 treatment group was compared to the vehicle group and the E2+ICI group was compared to the E2 group (* p < 0.05). Relative mRNA expression ZR-75-1 CERK 4 hr8 hr24 hr RPRM * * * KLF6 * * CLDN4 * * * EFEMP1 * 4 hr8 hr24 hr ENC1 4 hr8 hr24 hr A B Relative mRNA expression T47D RPRMKLF6 CERKEFEMP1 ENC1 CLDN4 * * * * * * * * * 4 hr8 hr24 hr4 hr8 hr24 hr4 hr8 hr24 hr

3 Fig S3 Fig S3: Identification of E2-repressed genes that are primary ERα targets. (A) MCF7 cells were treated with either vehicle, estrogen (E2), or a combination of E2 and cycloheximide (CHX). q-RT-PCR was used to calculate relative mRNA expression as ligand- mediated fold change compared to vehicle control. This fold change is reflected in the color intensity as shown in the legend. A 4h8h E2 CHX ++++ -++- E2 Fold change <0.3 0.3-0.5 0.5-0.7 0.7-0.9 1.3-1.5 1.5-1.9 >2 1.1-1.3 0.9-1.1 CLDN4 EFEMP1 CERK KLF6 ENC1 BIK HBP1 CXCR4 RAP1GA1 CDH3 BMP7 MXD4 NDRG1 RBL2 FLOT1 RND3 TENS1 IER3

4 Fig S4 Fig S4: Knockdown of HDAC1-10 and its effect on RPRM expression. MCF7 cells were transfected with non-specific siRNA (siNS) or siRNA against HDAC1-10 (siHDAC1-10) followed by either a vehicle or an E2 treatment for 12 hrs. The knockdown of each HDAC is shown in (A) and its effect on RPRM expression is shown in (B). q-RT-PCR was used to calculate relative mRNA expression as fold change compared to vehicle control. The data are an average of three replicates + SEM. A HDAC1HDAC2HDAC3HDAC4HDAC5 HDAC6HDAC7HDAC8HDAC9HDAC10 Relative mRNA expression siNSsiHDAC1siNSsiHDAC2siNSsiHDAC3siNSsiHDAC4siNSsiHDAC5 siNSsiHDAC6siNSsiHDAC7siNSsiHDAC8siNSsiHDAC9siNSsiHDAC10 B RPRM Relative mRNA expression siNSsiHDAC1siNSsiHDAC2siNSsiHDAC3siNSsiHDAC4siNSsiHDAC5 siNSsiHDAC6siNSsiHDAC7siNSsiHDAC8siNSsiHDAC9siNSsiHDAC10

5 Fig S5 Fig S5: Localization and expression of the HDAC7 deletion and mutant constructs. (A) 293 cells were transfected with Flag-HDAC, Flag-HDAC7 (1-487), Flag-HDAC7 (438-912), and Flag-HDAC7 (H670A) and immunostained for Flag. (B) 293 cells were transfected with Flag-HDAC, Flag-HDAC7 (1-487), Flag-HDAC7 (438-912), and Flag-HDAC7 (H670A) and blot for Flag and β-actin. B HDAC7: +---- --+- HDAC7 (1-487): - HDAC7 (438-912): ---- + HDAC7 (H670A): ---+ - β-actin Flag 100 75 45 50 150 MW (kDa) HDAC7HDAC7(1-487)HDAC7 (438-912)HDAC7 (H670A) A

6 * A SYBR Green assay was used for genes lacking a probe. *

7

Download ppt "Fig S1 Relative mRNA expression MCF7 pS2 * * * * * CCNG2 * * * * * * RPRM * * * * KLF6 * * * * * * CLDN4 * * * CERK * * * EFEMP1 * * * ENC1 * * BIK * *"

Similar presentations

Supplementary Fig. 1. Transcriptome analysis of MENX-associated pituitary adenomas and and comparison with human studies. Control samples from wild-type.

Supplementary Fig. 1. Transcriptome analysis of MENX-associated pituitary adenomas and and comparison with human studies. Control samples from wild-type.
Figure S1 A P

Figure S1 A P
Supplementary Figure 1. DAXX S564A does not change Mdm2/p53 stability or p53 ‑ mediated gene expression. (A) U2OS cells stably transduced with pCDH-DAXX.

Supplementary Figure 1. DAXX S564A does not change Mdm2/p53 stability or p53 ‑ mediated gene expression. (A) U2OS cells stably transduced with pCDH-DAXX.
Fig. 1 Screening for miRNAs that regulate primordial follicle assembly in mouse ovaries. (a) A flow chart of the screening strategy. miRNAs that expressed.

Fig. 1 Screening for miRNAs that regulate primordial follicle assembly in mouse ovaries. (a) A flow chart of the screening strategy. miRNAs that expressed.
Fig. 1 (A) (B) (C) * * * * Mock siRNA siRNA Day 3 Day 8 1 2 3 4 DNA-PKcs Beta actin.

Fig. 1 (A) (B) (C) * * * * Mock siRNA siRNA Day 3 Day DNA-PKcs Beta actin.
Supplemental Figure 1: ER  expression in MCF-7 cells. MCF-7 cells were either pre-treated with ICI 182,780 (lanes 5-8) or EtOH (vehicle, lanes 1-4) for.

Supplemental Figure 1: ER  expression in MCF-7 cells. MCF-7 cells were either pre-treated with ICI 182,780 (lanes 5-8) or EtOH (vehicle, lanes 1-4) for.
Sh-luc shSCP1-1 * IB: c-Myc IB: Tubulin shSCP1-2 IB: p-Ser62 1.0 1.8 2.5 60KD 70KD 60KD 70KD 1 2 3 (abnova) sh-luc shSCP1-1 * IB: c-Myc IB: Tubulin shSCP1-2.

Sh-luc shSCP1-1 * IB: c-Myc IB: Tubulin shSCP1-2 IB: p-Ser KD 70KD 60KD 70KD (abnova) sh-luc shSCP1-1 * IB: c-Myc IB: Tubulin shSCP1-2.
B Supplementary Fig S1. (A) ZR75- and MCF7-PELP1 knockdown cells were generated as described in methods section. Pooled colonies were analyzed for PELP1.

B Supplementary Fig S1. (A) ZR75- and MCF7-PELP1 knockdown cells were generated as described in methods section. Pooled colonies were analyzed for PELP1.
Supplemental Table S1 Table S1. Quantitative real-time RT-PCR primer sequences for genes used in the publication. All sequences are listed in the 5’ –

Supplemental Table S1 Table S1. Quantitative real-time RT-PCR primer sequences for genes used in the publication. All sequences are listed in the 5’ –
Fig. 1. GLP-1 induces miR-132 and miR-212 expression in pancreatic β-cells in vitro and in vivo. (A) MiRNA expression profiling of GLP-1 treated INS-1.

Fig. 1. GLP-1 induces miR-132 and miR-212 expression in pancreatic β-cells in vitro and in vivo. (A) MiRNA expression profiling of GLP-1 treated INS-1.
Supplementary Figure S1 FPKM ESRP1ESRP2 normaltumor Supplementary Figure S1. ESRP1 and ESRP2 mRNA expression in 65 normal kidney samples and 474 ccRCC.

Supplementary Figure S1 FPKM ESRP1ESRP2 normaltumor Supplementary Figure S1. ESRP1 and ESRP2 mRNA expression in 65 normal kidney samples and 474 ccRCC.
Supplementary Figure 1. Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer. (A-C) CDK7, CyclinH and MAT1 mRNA levels, determined by real-time.

Supplementary Figure 1. Expression of CDK7, cyclin H and MAT1 is elevated in breast cancer. (A-C) CDK7, CyclinH and MAT1 mRNA levels, determined by real-time.
Supplementary Figure S1. Knockdown of Twist1 mRNA increases Foxa1 expression in MDA-MB-436 cells. Total RNA and protein samples were prepared from MDA-MB-436.

Supplementary Figure S1. Knockdown of Twist1 mRNA increases Foxa1 expression in MDA-MB-436 cells. Total RNA and protein samples were prepared from MDA-MB-436.
Training Set Clinicopathological parameters of the training set

Training Set Clinicopathological parameters of the training set
Fig. 1 UGT2B15 mRNA levels are stimulated by E2 in a time- and dose-dependent manner in MCF-7 breast cancer cells. A, Time course for E2 treatment. Cells.

Fig. 1 UGT2B15 mRNA levels are stimulated by E2 in a time- and dose-dependent manner in MCF-7 breast cancer cells. A, Time course for E2 treatment. Cells.
Progesterone receptor

Progesterone receptor
Fig. 1. ER binding assays. (A) Mouse ER

Fig. 1. ER binding assays. (A) Mouse ER
Supplementary Figure 1: Clinical parameters of the breast tumor samples used for the study. IDC = Invasive ductal carcinoma and ILC= Invasive Lobular.

Supplementary Figure 1: Clinical parameters of the breast tumor samples used for the study. IDC = Invasive ductal carcinoma and ILC= Invasive Lobular.
Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.

Network protein vulnerability in EGFR TKI‐resistant cells and specific for EGFR‐mutated cells. Network protein vulnerability in EGFR TKI‐resistant cells.
CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

CDK4 is required for the hormone-independent growth of ER+ breast cancer cells. CDK4 is required for the hormone-independent growth of ER+ breast cancer.

Similar presentations

Ads by Google